Table 1.
Biomarkers to assess extracellular matrix turnover in serum
| Biomarker | Target | Detection range (nmol/L) | Intra‐assay and inter‐assay variability in human serum (%) | Corresponding pathology | Reference |
|---|---|---|---|---|---|
| P1NP | Internal epitope in the N‐terminal pro‐peptide of type I collagen | 12‐516 | 4.4 and 10.3 | Wound healing/fibrogenesis | 24 |
| C1M | Matrix metalloproteinase‐2/9/13 degraded type I collagen | 15‐460 | 10.1 and 6.7 | Inflammation/collagen degradation | 20 |
| Pro‐C3 | Released N‐terminal pro‐peptide of type III collagen | 2.6‐116 | 4.11 and 11.03 | Wound healing/fibrogenesis | 25 |
| C3M | Matrix metalloproteinase‐9 degraded type III collagen | 4‐88 | 2.2 and 2.15 | Inflammation/collagen degradation | 21 |
| Pro‐C5 | Released C‐terminal pro‐peptide of type V collagen | 130‐3120 | 3.46 and 5.09 | Wound healing/fibrogenesis | 26 |
| C5M | Matrix metalloproteinase‐2/9 degraded type V collagen | 1‐28 | 4.3 and 9.13 | Inflammation/collagen degradation | 22 |
| Pro‐C6 | C‐terminal of type VI collagen | 0.15‐58.39 | 4.8 and 15.2 | Wound healing/fibrogenesis | 27 |
| C6M | Matrix metalloproteinase‐2/9 degraded type VI collagen | 3‐210 | 4.1 and 10.11 | Inflammation/collagen degradation | 23 |